Home › Therapeutic areas › Oncology › Solid Tumors
Solid Tumors (21 companies)
Companies with an active program in Solid Tumors.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ADAG | Adagene | Oncology | 4 | Phase 2 | 10 |
| APVO | Aptevo Therapeutics | Oncology | 2 | Phase 1 | 8 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | 12 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 2 | NDA Submitted | 7 |
| CHRS | Coherus Oncology | Oncology | 1 | Approved | 3 |
| CGEN | Compugen | Oncology | 1 | Phase 3 | 7 |
| ERAS | Erasca | Oncology | 2 | Phase 1 | 3 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | 21 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 2 | Phase 2 | 10 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | 5 |
| IMNM | Immunome | Oncology Rare | 4 | NDA Submitted | 9 |
| MDNAF | Medicenna Therapeutics | Oncology | 1 | Phase 2 | 10 |
| INKT | MiNK Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | 8 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | 6 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | 8 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 1 | Phase 1 | 4 |
| CATX | Perspective Therapeutics | Oncology | 1 | Phase 1 | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | 7 |
| RXRX | Recursion Pharmaceuticals | Oncology | 4 | Phase 2 | 9 |
| STRO | Sutro Biopharma | Oncology | 3 | Phase 1 | 4 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | 28 |
No companies match.